SAN DIEGO, Aug. 10 /PRNewswire-FirstCall/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an
oncology company focused on the clinical development of novel
anti-cancer therapeutics, announced today the appointment of
Christine A. White, M.D., to its
board of directors. Dr. White replaces Professor Paul J. Nestel, who has served as a director
since April 2001.
"Dr. White brings a unique and valuable perspective to our board
as we continue to build a world-class oncology organization here in
the U.S.," said Daniel P. Gold,
Ph.D., President and Chief Executive Officer of Marshall Edwards. "Her deep understanding of
drug development and regulatory affairs coupled with her years of
experience treating patients as a clinical oncologist will be a
valuable asset to the company."
Dr. White was with Biogen Idec from 1996 to 2005, most recently
as Senior Vice President, Global Medical Affairs, where she played
an integral role in the clinical development, regulatory affairs
and commercialization of oncology drugs Rituxan® and Zevalin®.
Previously, she served as the Director of Clinical Oncology
Research at the Sidney Kimmel Cancer Center in San Diego, and in the Department of Medicine
at Scripps Memorial Hospitals in La
Jolla and Encinitas,
California, most recently as Chairman.
Dr. White currently serves as a member of the board of directors
of Arena Pharmaceuticals, a clinical-stage biopharmaceutical
company, and Genoptix, a specialized laboratory services provider.
She also served as a director of Pharmacyclics, a biopharmaceutical
company, and Monogram Biosciences, a life sciences company, until
its acquisition by LabCorp in August
2009. Dr. White earned her B.A. in Biology and her M.D. from
the University of Chicago and is Board
certified in both Internal Medicine and Medical Oncology.
"I am very pleased to welcome Dr. White to the board and look
forward to working with her as we strive to build long-term
shareholder value," said Professor Bryan
R.G. Williams, Chairman of the board of directors of
Marshall Edwards. "I also want to
take this opportunity on behalf of the entire board to thank
Professor Nestel for his years of dedicated service to Marshall Edwards."
About Marshall Edwards,
Inc.
Marshall Edwards, Inc. (NASDAQ:
MSHL) is a San Diego-based
oncology company focused on the clinical development of novel
anti-cancer therapeutics. These derive from an investigational
isoflavone technology platform, which has generated a number of
novel compounds characterized by direct targeting of tumor
metabolism. Specifically, these compounds are believed to target an
enzyme present in the cell membrane of cancer cells, thereby
inhibiting the production of pro-survival proteins within the cell.
Marshall Edwards has licensed rights
from Novogen Limited (ASX: NRT; Nasdaq: NVGN) for oncology drug
candidates Phenoxodiol, Triphendiol, NV-143 and NV-128. For more
information, please visit www.marshalledwardsinc.com.
Rituxan is a registered trademark of Genentech.
Zevalin is a registered trademark of Biogen Idec.
Under U.S. law, a new drug cannot be marketed until it has
been investigated in clinical trials and approved by the FDA as
being safe and effective for the intended use. Statements included
in this press release that are not historical in nature are
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements,
which are based on management's current expectations and are
subject to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our product
candidates; costs and delays in the development and/or FDA
approval, or the failure to obtain such approval, of our product
candidates; uncertainties or differences in interpretation in
clinical trial results; our inability to maintain or enter into,
and the risks resulting from our dependence upon, collaboration or
contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary rights to third
party patents and intellectual property to operate our business;
our inability to operate our business without infringing the
patents and proprietary rights of others; general economic
conditions; the failure of any products to gain market acceptance;
our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry
practice; and one-time events. We do not intend to update any of
these factors or to publicly announce the results of any revisions
to these forward-looking statements.
SOURCE Marshall Edwards, Inc.
Copyright . 10 PR Newswire